A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
The purpose of this study is to determine the immunogenicity and safety profile of CSL
 Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus
 Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18
 years.
Inclusion Criteria:

 -  Healthy male or non-pregnant female participants aged ≥ 6 calendar months to < 18
 years at the time of the first study vaccination.

 -  For participants aged ≥ 6 months to < 9 years, born after a normal gestation period
 (between 36 and 42 weeks).

 -  Females of childbearing potential (i.e., ovulating, pre-menopausal, not surgically
 sterile) must be abstinent or be willing to use a medically accepted contraceptive
 regimen for at least 2 months after vaccination. Females aged ≥ 9 years must also
 return a negative urine pregnancy test at enrollment.

 Exclusion Criteria:

 -  Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs,
 chicken protein, neomycin, polymyxin, or any components of the Study Vaccine.